Vtv Theraptcs Cl A (VTVT) Stock Price, Quote & News

Company Profile

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a lic...

Industry: Biotechnology

Sector: Healthcare

Phone: 336 841 0300

Fax: 336 841 0310

Website: vtvtherapeutics.com

Address:

3980 Premier Drive, Suite 310, High Point, United States

justiceforb_85 Aug. 24 at 12:50 AM

$VTVT when do they report P3 data?

1 · Reply

dcajic2 Aug. 20 at 7:09 PM

$VTVT have a few shares but will wait again to buy under $30. No real interest yet.

0 · Reply

GDS_investing Aug. 19 at 6:29 PM

if you love $AMLX and you missed yesterday's jump watch $VTVT It operates in the field of diabetes drug development. It is in Phase 3 of a major development program with a very high probability of success. Read all my posts on this subject. It is also recommended by many analysts. It has a very low market cap with tremendous potential. watch $MRNA $MRK long and strong $VTVT targets 44 56 84 120 240 480 after FDA

0 · Reply

dcajic2 Aug. 19 at 3:01 PM

$VTVT I bought shares under $30 so now the stock can now rise.

0 · Reply

GDS_investing Aug. 19 at 2:11 PM

$MRNA great $AGEN and $VTVT are next all long

0 · Reply

dcajic2 Aug. 17 at 2:29 PM

$VTVT under $30 seems like a good entry. Could be wrong though. So little is known when they will receive any data.

0 · Reply

dcajic2 Aug. 14 at 4:40 PM

$VTVT Adding a few to long side. Will add more when it falls further. The issue with this company is they have something great but have very poor leadership. They got breakthru therapy around Covid time and are still no where near fda approval.

0 · Reply

GDS_investing Aug. 14 at 3:54 PM

$ZIM nice add 150 shares $VTVT buy support area for long 44 then 56 and 84

0 · Reply

dcajic2 Aug. 14 at 3:51 PM

$VTVT loved the short. Called it again. May start a long position. Under $30

0 · Reply

dcajic2 Aug. 14 at 2:55 PM

$VTVT my predication of under $30 is so close. You have to wander why so many people have sold shares if they thought the stock was bullish.

0 · Reply

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2026-08-06T16:15:37.000Z - 17 days ago

vTv Therapeutics price target lowered to $42 from $45 at H.C. Wainwright

2026-08-06T13:15:51.000Z - 17 days ago

vTv Therapeutics reports Q2 EPS ($1.05), consensus (99c)

Aug 6, 2026, 8:00 AM EDT - 17 days ago

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 6, 2026, 7:00 AM EDT - 17 days ago

vTv Therapeutics Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 17 days ago

vTv Therapeutics Earnings release: Q2 2026

2026-07-16T11:20:34.000Z - 5 weeks ago

vTv Therapeutics price target raised to $57 from $49 at BTIG

2026-06-30T12:26:19.000Z - 7 weeks ago

vTv Therapeutics initiated with a Buy at Rodman & Renshaw

Jun 26, 2026, 11:00 AM EDT - 2 months ago

vTv Therapeutics Transcript: AGM 2026

Jun 10, 2026, 8:00 AM EDT - 2 months ago

vTv Therapeutics Proxy statement: Proxy filing

Jun 3, 2026, 5:05 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:05 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:04 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:04 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:03 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:03 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:03 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:02 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:02 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:02 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:01 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:01 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 1, 2026, 11:02 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 1, 2026, 11:02 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 1, 2026, 11:01 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 1, 2026, 10:58 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 1, 2026, 10:56 AM EDT - 2 months ago

vTv Therapeutics Earnings release

2026-05-13T20:13:15.000Z - 3 months ago

vTv Therapeutics reports Q1 EPS $1.65, consensus 21c

May 13, 2026, 4:01 PM EDT - 3 months ago

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026, 8:00 AM EDT - 3 months ago

vTv Therapeutics to Participate in Upcoming May Investor Conferences

Mar 23, 2026, 2:00 PM EDT - 5 months ago

vTv Therapeutics Transcript: 38th Annual Roth Conference

Mar 16, 2026, 8:00 AM EDT - 5 months ago

vTv Therapeutics to Participate in the 38th Annual ROTH Conference

2026-03-12T10:46:05.000Z - 5 months ago

vTv Therapeutics initiated with an Outperform at Evercore ISI

2026-03-11T11:11:56.000Z - 5 months ago

vTv Therapeutics price target raised to $55 from $35 at Alliance Global

2026-03-10T20:11:02.000Z - 5 months ago

vTv Therapeutics reports Q4 EPS (58c), consensus ($1.09)

Mar 10, 2026, 4:01 PM EDT - 5 months ago

vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 3, 2026, 9:50 AM EST - 6 months ago

vTv Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 13, 2026, 8:00 AM EST - 6 months ago

vTv Therapeutics to Participate in Upcoming Investor Conferences

2026-02-02T13:15:17.000Z - 7 months ago

vTv Therapeutics expanded its license agreement with Newsoara Biopharma

Feb 2, 2026, 8:00 AM EST - 7 months ago

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

2026-01-27T12:25:32.000Z - 7 months ago

vTv Therapeutics price target raised to $49 from $40 at BTIG

2026-01-22T21:11:50.000Z - 7 months ago

vTv Therapeutics initiated with a Buy at Roth Capital

2026-01-05T10:50:07.000Z - 8 months ago

vTv Therapeutics initiated with a Buy at TD Cowen

2025-12-19T13:20:18.000Z - 8 months ago

vTv Therapeutics price target raised to $47 from $36 at H.C. Wainwright

2025-12-18T21:10:54.000Z - 8 months ago

vTv submits cadisegliatin study protocol to Department of Health Abu Dhabi

Dec 18, 2025, 4:05 PM EST - 8 months ago

vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

2025-11-18T21:20:58.000Z - 9 months ago

vTv Therapeutics initiated with a Buy at BTIG

2025-11-06T22:30:59.000Z - 10 months ago

vTv Therapeutics reports Q3 EPS ($1.08), consensus (98c)

Nov 6, 2025, 4:15 PM EST - 10 months ago

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

2025-11-05T14:42:37.000Z - 10 months ago

vTv Therapeutics trading resumes

2025-11-05T14:36:57.000Z - 10 months ago

vTv Therapeutics trading halted, volatility trading pause

2025-10-09T12:11:55.000Z - 11 months ago

vTv Therapeutics announces three appointments to Scientific Advisory Board

Oct 9, 2025, 8:00 AM EDT - 11 months ago

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

2025-10-03T20:45:20.000Z - 11 months ago

vTv Therapeutics files to sell 15.88M shares of Class A common stock for holders

Sep 15, 2025, 8:00 AM EDT - 1 year ago

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

Sep 3, 2025, 4:57 PM EDT - 1 year ago

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 1 year ago

vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 2, 2025, 8:00 AM EDT - 1 year ago

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

Aug 12, 2025, 4:15 PM EDT - 1 year ago

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 8:00 AM EDT - 1 year ago

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

Aug 7, 2025, 8:00 AM EDT - 1 year ago

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

Jun 11, 2025, 8:00 AM EDT - 1 year ago

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

May 19, 2025, 9:00 AM EDT - 1 year ago

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 15, 2025, 4:01 PM EDT - 1 year ago

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025, 12:00 PM EDT - 1 year ago

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

Mar 20, 2025, 5:35 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 17, 2025, 8:30 AM EDT - 1 year ago

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Dec 9, 2024, 7:33 AM EST - 1 year ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Dec 2, 2024, 4:05 PM EST - 1 year ago

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

Aug 8, 2024, 4:15 PM EDT - 2 years ago

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Jul 26, 2024, 4:05 PM EDT - 2 years ago

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Jun 24, 2024, 4:05 PM EDT - 2 years ago

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

May 28, 2024, 8:00 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

May 9, 2024, 4:51 PM EDT - 2 years ago

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

Mar 19, 2024, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Mar 13, 2024, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 4, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Mar 1, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

Feb 28, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

Feb 22, 2024, 4:00 PM EST - 2 years ago

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Nov 9, 2023, 4:30 PM EST - 3 years ago

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Nov 8, 2023, 8:00 AM EST - 3 years ago

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

Nov 2, 2023, 8:00 AM EDT - 3 years ago

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Nov 1, 2023, 8:00 AM EDT - 3 years ago

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Sep 27, 2023, 8:30 AM EDT - 3 years ago

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

$Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer$

Sep 26, 2023, 8:30 AM EDT - 3 years ago

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Sep 18, 2023, 8:30 AM EDT - 3 years ago

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

Aug 11, 2023, 4:30 PM EDT - 3 years ago

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Aug 10, 2023, 8:33 AM EDT - 3 years ago

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Jun 16, 2023, 8:00 AM EDT - 3 years ago

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

Jun 15, 2023, 7:33 AM EDT - 3 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

May 24, 2023, 9:00 AM EDT - 3 years ago

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 11, 2023, 4:15 PM EDT - 3 years ago

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

justiceforb_85 Aug. 24 at 12:50 AM

$VTVT when do they report P3 data?

1 · Reply

dcajic2 Aug. 20 at 7:09 PM

$VTVT have a few shares but will wait again to buy under $30. No real interest yet.

0 · Reply

GDS_investing Aug. 19 at 6:29 PM

0 · Reply

dcajic2 Aug. 19 at 3:01 PM

$VTVT I bought shares under $30 so now the stock can now rise.

0 · Reply

GDS_investing Aug. 19 at 2:11 PM

$MRNA great $AGEN and $VTVT are next all long

0 · Reply

dcajic2 Aug. 17 at 2:29 PM

$VTVT under $30 seems like a good entry. Could be wrong though. So little is known when they will receive any data.

0 · Reply

dcajic2 Aug. 14 at 4:40 PM

0 · Reply

GDS_investing Aug. 14 at 3:54 PM

$ZIM nice add 150 shares $VTVT buy support area for long 44 then 56 and 84

0 · Reply

dcajic2 Aug. 14 at 3:51 PM

$VTVT loved the short. Called it again. May start a long position. Under $30

0 · Reply

dcajic2 Aug. 14 at 2:55 PM

$VTVT my predication of under $30 is so close. You have to wander why so many people have sold shares if they thought the stock was bullish.

0 · Reply

dcajic2 Aug. 11 at 7:09 PM

$VTVT shorts working out again. Just seems if there is higher volume and the stock is red it is not bullish. This company has always been very weak with communication.

0 · Reply

dcajic2 Aug. 11 at 4:43 PM

$VTVT Not bullish yet. Good volume yet the stock is falling.

0 · Reply

dcajic2 Aug. 11 at 4:42 PM

$VTVT another short working out .

0 · Reply

dcajic2 Aug. 11 at 4:21 PM

$VTVT if stock is so bullish at this time then why is it not green? Why are people selling if they think they can get $67? Without news I am still thinking under $30 Will come.

0 · Reply

GDS_investing Aug. 11 at 3:44 PM

$VTVT love the volume today very low float "TD Cowen Maintains VTv Therapeutics(VTVT) With Buy Rating, Maintains Target Price $67 !!! " huge upside here ! LONG AND STRONG VTVT TARGETS $44 56 $84 120 - 240 - 480 after fda watch $PALG.X $MSGY $LABU $WXM

0 · Reply

dcajic2 Aug. 11 at 2:45 PM

$VTVT still like my chances of buying under $30. Communication is weak yet someone knows something with high volume.

0 · Reply

dcajic2 Aug. 11 at 2:43 PM

$VTVT volume is great yet it is red. Why would so many people be selling without news if they thought for a minute it was bullish.

0 · Reply

dcajic2 Aug. 10 at 4:13 PM

$VTVT still like the short. As the day us go by without communication the stock is likely to go below $30.

0 · Reply

prismmarketview Aug. 7 at 6:50 PM

$VTVT vTv Therapeutics Inc. reported Q2 2026 results with $86.6 million in cash—funding operations through its expected Phase 3 CATT1 trial readout—and confirmed enrollment in the type 1 diabetes study remains on track to complete in Q3 2026. https://prismmarketview.com/companies/vtv-therapeutics-inc/#news

0 · Reply

GDS_investing Aug. 7 at 4:15 PM

$VTVT wow What happened?

0 · Reply

jarich7 Aug. 7 at 4:10 PM

$VTVT

0 · Reply

GDS_investing Aug. 7 at 3:37 PM

$VTVT looking good need more volume next target 38.5 then 44 and 56 84 long

0 · Reply

Market Cap	130.99M
Revenue (ttm)	0.00
Net Income (ttm)	-26.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	26,600
Avg Vol	81,794
Day's Range	N/A - N/A
Shares Out	3.94M
Stochastic %K	58%
Beta	0.28
Analysts	Strong Sell
Price Target	$55.71